A patient is scheduled for surgery tomorrow morning. During medication reconciliation, you notice they took their weekly semaglutide dose two days ago. They feel fine, but anesthesia is concerned about aspiration risk. Meanwhile, glucose levels are creeping up. Do you hold the medication, continue it, or change course entirely? Situations …

The scale is moving fast, clothes are fitting better, and blood sugar numbers are improving. For many people using GLP-1 medications, weight loss can feel almost effortless at first. Yet beneath those encouraging changes, another question often emerges: is muscle being lost along with fat? For individuals focused on long-term …

What happens when a medication that quietly supports weight loss and glucose control suddenly disappears? For many patients, an unexpected break in GLP-1 therapy feels like pulling the rug out from under hard-earned progress. Supply shortages, insurance denials, side effects, or planned drug holidays are now common reasons people stop …

A patient returns for follow-up after starting a GLP-1 receptor agonist and mentions something unexpected. Their blood glucose is improved, weight is down, and their psoriasis seems quieter. Another patient reports fewer hidradenitis flares. These anecdotes are becoming more common, raising a practical question for clinicians. Are GLP-1 therapies influencing …

A patient with type 2 diabetes finally achieves better glycemic control on a GLP-1 receptor agonist. Weight is coming down, A1C is improving, and cardiovascular risk looks more manageable. Then an unexpected comment appears at a follow-up visit. Their joints feel better. For clinicians, moments like this raise an important …

GLP-1–based therapies have quickly become a cornerstone of modern diabetes care. While most clinicians think of these agents for glucose lowering and weight loss, growing evidence suggests they may also support better blood pressure control. For patients living with diabetes and hypertension, that overlap raises an important question. Can GLP-1 …

What happens when breakthrough treatments only reach the few who can afford or access them? That’s the growing dilemma in diabetes care. As GLP‑1 medications, digital tools, and AI reshape how we treat this chronic disease, the risk is clear: innovation could deepen inequality if we don’t act intentionally. Equity …

What happens when a guideline finally reflects the complex realities of patient care? The ADA’s 2026 CKM standards aim to do just that—merging heart, kidney, and metabolic health into one actionable framework. But translating those recommendations into daily clinical decision-making isn’t always straightforward. This article walks through real-world composite cases …

What if your next diabetes appointment started before you even walked in—an algorithm already having reviewed your CGM data, flagged risks, and drafted a care plan? That’s not science fiction. It’s the emerging reality of AI-powered workflows for diabetes care, where intelligent systems work behind the scenes to support clinicians …

A patient walks into your exam room, hopeful after reading that a diabetes drug might help with memory loss, addiction, or even anxiety. You know they’re talking about GLP‑1s—but how do you respond when the science is still unfolding? As GLP‑1 receptor agonists capture public attention for much more than …